Navigation Links
Covance Agrees to Enter Strategic Relationship with eResearchTechnology to Offer its Clients eRT's Centralized Cardiac Safety Services
Date:11/27/2007

- Covance Sells Centralized ECG Business; Enters Exclusive Ten Year

Marketing Agreement with eRT -

PRINCETON, N.J., Nov. 27 /PRNewswire-FirstCall/ -- Covance Inc. (NYSE: CVD) announced today that it has agreed to sell its centralized ECG business to eResearchTechnology (eRT) and enter into a ten year marketing agreement to offer its clients cardiac safety services through eRT's robust centralized ECG platform. The transactions are expected to be completed on or before November 28, 2007.

"Covance remains fully committed to providing our clients with integrated drug development solutions, including critical cardiac safety data in clinical projects," said Joe Herring, Chairman and CEO of Covance. "Under the new marketing arrangement, we believe our clients will benefit from eRT's industry-leading centralized ECG services. The transaction also allows Covance's management team to focus more attention and investments on growing our service offerings in the larger markets we serve."

"By engaging in this long-term strategic relationship with the world's largest publicly-traded CRO, eRT is extending its leadership position in the area of cardiac safety," said Dr. Michael McKelvey, President and CEO of eRT. "The scale, expertise, and ancillary technology benefits that will be derived from the acquisition will allow us to provide better and more cost-effective services to our valued clients and to the drug development industry."

In exchange for its centralized ECG business, which accounted for less than 2% of the company's annual net revenues, Covance disclosed that it has received an upfront cash payment from eRT of approximately $35 million with the opportunity to receive up to an additional $14 million in contingent consideration relating to the transferred backlog as well as from revenues generated from new contracts secured under the long-term marketing arrangement. In addition, Covance expects to receive certain referral fees over the term of the marketing agreement.

Covance is maintaining its full-year 2007 earnings target of $2.65 per diluted share, excluding any gain resulting from the sale of its centralized ECG business. In 2008, Covance continues to target revenue growth in the low- to mid-teens range and diluted earnings per share growth of 20%, excluding any gain resulting from any future contingent consideration received from the sale of the centralized ECG business.

Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with revenues over the last twelve months of approximately $1.5 billion, global operations in more than 20 countries, and approximately 8,700 employees worldwide. Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at http://www.covance.com.

Based in Philadelphia, Pennsylvania, eResearchTechnology, Inc. (http://www.eRT.com) is a provider of technology and services to the pharmaceutical, biotechnology, and medical device industries on a global basis. The Company is a market leader in providing centralized core-diagnostic electrocardiographic (ECG) technology and services to evaluate cardiac safety in clinical development. The Company is also a leader in providing technology and services to streamline the clinical trials process by enabling its customers to automate the collection, analysis, and distribution of clinical data in all phases of clinical development.

Statements contained in this press release, which are not historical facts, such as statements about prospective earnings, savings, revenue, operations, revenue and earnings growth and other financial results are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements including the statements contained herein regarding anticipated trends in the Company's business are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, competitive factors, outsourcing trends in the pharmaceutical industry, levels of industry research and development spending, the Company's ability to continue to attract and retain qualified personnel, the fixed price nature of contracts or the loss of large contracts, risks associated with acquisitions and investments, the Company's ability to increase order volume, the pace of translation of orders into revenue in late-stage development services, and other factors described in the Company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no duty to update any forward looking statement to conform the statement to actual results or changes in the Company's expectations.


'/>"/>
SOURCE Covance Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Covance to Present at the UBS Global Life Sciences Conference
2. Covance Elects Dr. Gary E. Costley to Board of Directors
3. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
4. Wild American Shrimp Board Agrees To Implement New Self-Funding Measures
5. Medical Services International Agrees to Retail the VScan Hepatitis B&C Test Kits in SE Asia
6. CSC Agrees to Acquire First Consulting Group
7. Scientists Spot Brains Free Will Center
8. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
9. Providence St. Joseph Medical Center, Caregivers Reach Agreement on a Union Contract
10. 4-Star Gen. Barry McCaffrey, Former U.S. Drug Czar, to Address National Drug Crisis, Keynote Grand Opening of New Allenwood, PA National Model Detox Center
11. Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 2016 , ... The OSHA Training Center at Chabot-Las ... headquartered in Northern California, has issued an important reminder to employers to prevent ... Employers with workers exposed to high temperatures should establish a complete heat illness ...
(Date:6/27/2016)... Viejo, California (PRWEB) , ... June 27, 2016 , ... ... are fully customizable inside of Final Cut Pro X," said Christina Austin - CEO ... another unique style. Final Cut Pro X users can now reveal the ...
(Date:6/27/2016)... ... ... TherapySites, the leading website and online marketing ... Association. This new relationship allows TherapySites to continue to extend their online ... and promotional offers. , "TCA is extremely excited about this new partnership, as ...
(Date:6/27/2016)... ... June 27, 2016 , ... ePAY ... partnership with Connance, a healthcare industry leader providing predictive analytics to optimize ... combine to provide health systems, hospitals and ambulatory surgical centers with dramatic ...
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution is ... emergency ambulance transport experience for the millions of people who require these medical ... the taxi industry through the use of technology. Now, SmartEMS has put forth ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Dehaier Medical Systems Ltd. (NASDAQ: ... and sells medical devices and wearable sleep respiratory products ... cooperation agreement with Hongyuan Supply Chain Management Co., Ltd. ... 20, 2016, to develop Dehaier,s new Internet medical technology ... will leverage Hongyuan Supply Chain,s sales platform to reach ...
(Date:6/24/2016)... , June 24, 2016 Research and ... Market for Companion Diagnostic Tests" report to their offering. ... for Companion Diagnostics The World Market for ... personalized medicine diagnostics. Market analysis in the report includes the ... Market (In Vitro Diagnostic Kits) by Region (N. America, EU, ...
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ., ... developing innovative inhaled drugs, announced today that it was ... Investments reconstituted its comprehensive set of U.S. and ... "This is an important milestone for Pulmatrix," said Chief ... shareholder awareness of our progress in developing drugs for ...
Breaking Medicine Technology: